2025 ESC/EACTS重度三尖瓣反流推荐在真实世界中的应用
研究基于EuroTR注册数据,对1626例接受三尖瓣经导管缘对缘修复(T-TEER)患者应用2025 ESC/EACTS指南中左室功能不全(LVD)、右室功能不全(RVD)及毛细血管前肺动脉高压(pcPH)阈值,比较「OMT候选者」与「TTVI适用」患者的预后。结果显示OMT候选者2年免心衰住院生存率更低(58.7% vs 74.3%,P<0.001),但症状改善比例相当,提示T-TEER或可使部分高危患者获益。
要点
- 合并重度LVD、RVD或pcPH者免心衰住院生存率显著低于对照人群。
- OMT候选者与TTVI适用者的NYHA分级改善比例无显著差异。
- 高危患者行T-TEER需在多学科心脏瓣膜中心评估获益与无效风险。
核心结论
- T-TEER可能为合并重度LVD、RVD或pcPH的选定高危重度三尖瓣反流患者带来症状获益。
- 在缺乏随机证据的情况下,仍需在经验丰富的心脏瓣膜中心进行多学科评估,以权衡潜在获益与手术无效风险。
研究设计与样本
- 研究基于EuroTR(欧洲三尖瓣反流经导管修复注册研究)数据,纳入1626例接受三尖瓣经导管缘对缘修复(T-TEER)的患者。
- 将2025 ESC/EACTS指南中LVD、RVD和pcPH的阈值应用于上述患者,符合≥1项排除标准者定义为「OMT候选者」,与「TTVI适用」患者进行比较。
- 比较指标为NYHA心功能分级改善及2年免心衰住院(HFH)生存,随访生存期中位数446天(Q1-Q3:192-805天)。
主要发现
- 1626例T-TEER患者中213例(13.1%)符合≥1项排除标准,其中LVD占4.2%、RVD占6.8%、pcPH占3.6%。
- 重度LVD、RVD、pcPH分别与更低的一年免HFH生存相关:LVD 54.6% vs 72.9%(P<0.001);RVD 59.0% vs 73.2%(P=0.003);pcPH 56.2% vs 73.4%(P=0.021)。
- 尽管基线与随访时NYHA分级更高,各亚组≥1级改善率相当:LVD 51.1% vs 59.4%(P=0.25);RVD 59.7% vs 59.0%(P=0.90);pcPH 51.3% vs 59.4%(P=0.31)。
- 总体「OMT候选者」免HFH生存低于「TTVI适用」患者(58.7% vs 74.3%;P<0.001),但症状缓解相当(≥1级NYHA改善56.2% vs 59.5%;P=0.68)。
关键数值与推荐
- 2025 ESC/EACTS瓣膜性心脏病指南对重度症状性三尖瓣反流的经导管三尖瓣介入(TTVI)给出IIa类推荐(证据级别A)。
- 对合并重度左室功能不全、右室功能不全或毛细血管前肺动脉高压者,指南因潜在无效风险更倾向于最佳药物治疗(OMT)。
临床怎么用
- 对合并重度LVD、RVD或pcPH的重度三尖瓣反流患者,T-TEER前应在经验丰富的心脏瓣膜中心行多学科评估。
- 应向此类高危患者说明免心衰住院生存可能较低,但症状改善可能与指南适用人群相当。
局限性
- 本研究为注册数据分析,缺乏随机对照证据。
- 「OMT候选者」样本量相对较小(213例),各亚组分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JACC Cardiovasc Interv. 2026 Apr 13;19(7):843-853. doi: 10.1016/j.jcin.2026.02.024. ABSTRACT BACKGROUND: According to the 2025 ESC/EACTS guidelines for the management of valvular heart disease, transcatheter tricuspid valve interventions (TTVI) have received a Class IIa recommendation (Level of Evidence: A) for the treatment of patients with severe symptomatic tricuspid regurgitation. However, in patients with severe left ventricular dysfunction (LVD) or right ventricular dysfunction (RVD) or precapillary pulmonary hypertension (pcPH), optimal medical therapy (OMT) is preferred because of the potential risk for futility. OBJECTIVES: The aim of this study was to evaluate clinical and symptomatic outcomes in such "OMT candidate" patients. METHODS: Using data from EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation), guideline-based thresholds for LVD, RVD, and pcPH were applied to patients undergoing tricuspid valve transcatheter edge-to-edge repair (T-TEER). Patients meeting ≥1 exclusion criterion ("OMT candidates") were compared with those meeting current recommendations ("TTVI appropriate") regarding NYHA functional class improvement and 2-year survival free from heart failure hospitalization (HFH). RESULTS: Among 1,626 T-TEER patients, 213 (13.1%) met ≥1 exclusion criterion (4.2% of those with LVD, 6.8% of those with RVD, and 3.6% of those with pcPH). Severe LVD, RVD, and pcPH were each associated with significantly lower 1-year HFH-free survival (LVD, 54.6% vs 72.9% [P < 0.001]; RVD, 59.0% vs 73.2% [P = 0.003]; pcPH, 56.2% vs 73.4% [P = 0.021]; median survival follow-up 446 days [Q1-Q3: 192-805 days]). Despite higher NYHA functional class at baseline and follow-up, the rate of ≥1-class improvement was comparable across subgroups (LVD, 51.1% vs 59.4% [P = 0.25]; RVD, 59.7% vs 59.0% [P = 0.90]; pcPH, 51.3% vs 59.4% [P = 0.31]). Overall, "OMT candidates" had lower HFH-free survival than "TTVI-appropriate" patients (58.7% vs 74.3%; P < 0.001) but showed comparable symptomatic relief (≥1 NYHA functional class in 56.2% vs 59.5%; P = 0.68). CONCLUSIONS: T-TEER may provide symptomatic benefit in selected high-risk patients with severe LVD, RVD, or pcPH. In the absence of randomized evidence, multidisciplinary evaluation at experienced heart valve centers remains essential to balance potential benefit against procedural futility. Further studies are warranted to refine patient selection and optimize outcomes in this challenging cohort.
引用
- 指南共识 · 肺动脉高压:Applying the 2025 ESC/EACTS Recommendations for the Treatment of Severe Tricuspid Regurgitation to Real-World Practice
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。